Kiniksa Pharmaceuticals International, plc (KNSA)Healthcare | Drug Manufacturers - Specialty & Generic | London, United Kingdom | NasdaqGS
60.94 USD
-2.50
(-3.941%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 60.43 -0.51 (-0.510%) ⇩ (July 13, 2026, 7:51 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:27 a.m. EDT
The immediate outlook is aggressively bullish, driven by a perfect storm of technical breakout and institutional validation. The stock recently joined the Russell Indexes, triggering a surge that pushed it to a new 12-month high and ignited a powerful momentum engine. Technicals confirm this shift: the price is trading significantly above both the 50-day and 200-day averages, indicating strong institutional accumulation. This is further corroborated by the options flow, where traders are overwhelmingly buying calls with minimal hedging via puts, signaling a high-conviction bet on continued appreciation. While the statistical forecasting model offers no directional guidance due to low confidence, this noise metric is irrelevant against the backdrop of such robust fundamental and technical strength. Fundamentally, the company shows exceptional health with a fortress balance sheet (minimal debt, massive cash reserves), accelerating revenue growth of 55%, and expanding margins. However, the valuation remains stretched with a trailing P/E of nearly 70x, reflecting the market's premium for this growth trajectory. The lack of a dividend is appropriate for a high-growth biotech firm in this expansion phase. The primary risk is the potential for a sharp correction if the stock fails to sustain its recent pace, but the current setup favors the bulls. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.177089 |
| AutoETS | 0.220645 |
| MSTL | 0.220649 |
| AutoTheta | 0.239606 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 0.96 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.440 |
| Excess Kurtosis | -0.91 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.49 |
| Revenue per Share | 10.031 |
| Market Cap | 4,688,602,624 |
| Trailing P/E | 70.05 |
| Forward P/E | 35.79 |
| Beta | 0.07 |
| Profit Margins | 9.69% |
| Previous Name | Kiniksa Pharmaceuticals, Ltd. |
| Website | https://www.kiniksa.com |
As of July 11, 2026, 3:27 a.m. EDT: Speculators are heavily positioned for upside continuation with massive open interest in out-of-the-money calls (OTM OI % near 100% for near-term expirations), while put activity is negligible and concentrated deep in-the-money. Implied volatility is elevated for near-term strikes, suggesting a bullish gamma squeeze or momentum play rather than hedging.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.2027779 |
| Address1 | 105 Piccadilly |
| Address2 | 2nd Floor |
| All Time High | 67.53 |
| All Time Low | 5.01 |
| Ask | 78.1 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 1,478,480 |
| Average Daily Volume3 Month | 829,118 |
| Average Volume | 829,118 |
| Average Volume10Days | 1,478,480 |
| Beta | 0.07 |
| Bid | 45.31 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 8.219 |
| City | London |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 60.94 |
| Current Ratio | 3.794 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 63.43 |
| Day Low | 60.89 |
| Debt To Equity | 1.49 |
| Display Name | Kiniksa Pharmaceuticals |
| Earnings Call Timestamp End | 1,777,379,400 |
| Earnings Call Timestamp Start | 1,777,379,400 |
| Earnings Growth | 1.455 |
| Earnings Quarterly Growth | 1.646 |
| Earnings Timestamp | 1,777,379,400 |
| Earnings Timestamp End | 1,785,241,800 |
| Earnings Timestamp Start | 1,785,241,800 |
| Ebitda | 94,893,000 |
| Ebitda Margins | 0.12585 |
| Enterprise To Ebitda | 44.572 |
| Enterprise To Revenue | 5.609 |
| Enterprise Value | 4,229,534,720 |
| Eps Current Year | 1.16 |
| Eps Forward | 1.7025 |
| Eps Trailing Twelve Months | 0.87 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 55.7759 |
| Fifty Day Average Change | 5.164097 |
| Fifty Day Average Change Percent | 0.092586525 |
| Fifty Two Week Change Percent | 120.27779 |
| Fifty Two Week High | 67.53 |
| Fifty Two Week High Change | -6.59 |
| Fifty Two Week High Change Percent | -0.09758626 |
| Fifty Two Week Low | 26.27 |
| Fifty Two Week Low Change | 34.67 |
| Fifty Two Week Low Change Percent | 1.3197563 |
| Fifty Two Week Range | 26.27 - 67.53 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,527,255,000,000 |
| Float Shares | 42,200,502 |
| Forward Eps | 1.7025 |
| Forward P E | 35.79442 |
| Free Cashflow | 117,572,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 366 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.54654 |
| Gross Profits | 412,112,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03579 |
| Held Percent Institutions | 1.02644 |
| Implied Shares Outstanding | 76,938,016 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom. |
| Long Name | Kiniksa Pharmaceuticals International, plc |
| Market | us_market |
| Market Cap | 4,688,602,624 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_558211765 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | 73,058,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,880,947,733 |
| Number Of Analyst Opinions | 8 |
| Open | 63.43 |
| Operating Cashflow | 165,860,000 |
| Operating Margins | 0.13659 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 44 78 1431 9100 |
| Post Market Change | -0.5099983 |
| Post Market Change Percent | -0.836886 |
| Post Market Price | 60.43 |
| Post Market Time | 1,783,986,684 |
| Prev Name | Kiniksa Pharmaceuticals, Ltd. |
| Previous Close | 63.44 |
| Price Eps Current Year | 52.534485 |
| Price Hint | 2 |
| Price To Book | 7.4145274 |
| Price To Sales Trailing12 Months | 6.2179346 |
| Profit Margins | 0.09689 |
| Quick Ratio | 3.137 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.125 |
| Region | US |
| Regular Market Change | -2.5 |
| Regular Market Change Percent | -3.94073 |
| Regular Market Day High | 63.43 |
| Regular Market Day Low | 60.89 |
| Regular Market Day Range | 60.89 - 63.43 |
| Regular Market Open | 63.43 |
| Regular Market Previous Close | 63.44 |
| Regular Market Price | 60.94 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 586,017 |
| Return On Assets | 0.08179 |
| Return On Equity | 0.13743 |
| Revenue Growth | 0.555 |
| Revenue Per Share | 10.031 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 46,303,276 |
| Shares Percent Shares Out | 0.054 |
| Shares Short | 4,154,751 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,042,330 |
| Short Name | Kiniksa Pharmaceuticals Interna |
| Short Percent Of Float | 0.1093 |
| Short Ratio | 4.3 |
| Source Interval | 15 |
| Symbol | KNSA |
| Target High Price | 78.0 |
| Target Low Price | 60.0 |
| Target Mean Price | 68.125 |
| Target Median Price | 68.5 |
| Total Cash | 468,092,992 |
| Total Cash Per Share | 6.084 |
| Total Debt | 9,025,000 |
| Total Revenue | 754,044,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.87 |
| Trailing P E | 70.045975 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 45.79425 |
| Two Hundred Day Average Change | 15.145748 |
| Two Hundred Day Average Change Percent | 0.3307347 |
| Type Disp | Equity |
| Volume | 586,017 |
| Website | https://www.kiniksa.com |
| Zip | W1J 7NJ |